Anti-CD19 CAR-T therapy, employing a DNA-based approach with lymphodepleting conditioning, has demonstrated promising outcomes in three reported refractory MG cases: one AChR-positive and two with concomitant Lambert-Eaton myasthenic syndrome (LEMS), achieving effective CD19-positive B-cell depletion and significant clinical improvement over two to six months of follow-up [73,74]. This evidence concerns the gene CD19 and Lambert-Eaton myasthenic syndrome.